Conjunctivitis in COVID-19 patients: frequency and clinical presentation
- PDF / 318,499 Bytes
- 7 Pages / 595.276 x 790.866 pts Page_size
- 66 Downloads / 211 Views
INFLAMMATORY DISORDERS
Conjunctivitis in COVID-19 patients: frequency and clinical presentation Noemi Güemes-Villahoz 1 & Barbara Burgos-Blasco 1 & Julián García-Feijoó 2 & Federico Sáenz-Francés 2 & Pedro Arriola-Villalobos 2 & Jose María Martinez-de-la-Casa 2 & Jose Manuel Benítez-del-Castillo 2 & María Herrera de la Muela 3 Received: 1 June 2020 / Revised: 20 July 2020 / Accepted: 25 August 2020 # Springer-Verlag GmbH Germany, part of Springer Nature 2020
Abstract Purpose The purpose of this study was to evaluate the frequency and clinical presentation of conjunctivitis in hospitalized patients with COVID-19. Methods A cross-sectional study was conducted at the Hospital Clinico San Carlos of Madrid, Spain. A total of 301 subjects from the COVID admission unit with laboratory-confirmed SARS-CoV-2 infection were included. The presence and clinical characteristics of conjunctivitis were evaluated. Laboratory, radiological, and clinical results in patients with and without conjunctivitis stratified by sex were analyzed. Results Of the 301 subjects included, 180 patients (59.8%) were male and the median age was 72 years (IQ 59–82). Overall, 35 patients (11.6%) were diagnosed with acute conjunctivitis. We found no relationship between the COVID-19 severity score and the presence of conjunctivitis (P = 0.17). However, conjunctivitis was more frequent in males with moderate clinical severity and in women classified as clinically mild. The natural history of the disease seems to be a rapid self-limited conjunctivitis that improves without treatment and does not affect visual acuity nor associate short-term complications. Conclusions Approximately, 1 out of 10 hospitalized non-critical COVID-19 patients presents conjunctivitis during the disease. Compared with other viral conjunctivitis, we found distinctive clinical findings that could guide defining and differentiating conjunctivitis in COVID-19 patients. Trial registration number 20/336_E_COVID Keywords Conjunctivitis . COVID-19 . SARS-CoV-2 . Ocular . Coronavirus
Introduction A novel coronavirus (CoV) named severe acute respiratory syndrome coronavirus–2 (SARS-CoV-2) emerged from * Barbara Burgos-Blasco [email protected] 1
Department of Ophthalmology, Hospital Clínico San Carlos, Calle del Prof Martín Lagos, s/n, 28040 Madrid, Spain
2
Department of Ophthalmology, Hospital Clinico San Carlos, Instituto de investigación sanitaria del Hospital Clínico San Carlos (IsISSC). IIORC, Universidad Complutense de Madrid, ISCIII (OFTARED), Madrid, Spain
3
Obstetrics and Gynecology Department, Hospital Clinico San Carlos, Instituto de salud de la mujer. Instituto de investigación sanitaria del Hospital Clínico San Carlos (IsISSC), Madrid, Spain
China in December 2019. This virus causes the coronavirus disease 2019 (COVID-19), which is having an extraordinary impact worldwide [1, 2]. The references in the medical literature regarding the ocular manifestations of this emerging disease are scarce so far and, despite the fact that ocular involvement is not well defined y
Data Loading...
